Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Novavax Workforce Reduction


Novavax, a vaccine maker based in Gaithersburg, Md., managed to decrease its losses in the fourth quarter by cutting its headcount.

In the period ended Dec. 31, Novavax reported a loss of $178.39 million, or $1.44 per share, which was an improvement compared to the loss of $182.25 million, or $2.28 per share, from the same period a year ago. Despite this positive development, analysts surveyed by FactSet had forecasted a loss of 48 cents per share.

Sales also saw a decline, dropping to $291.34 million from $357.4 million in the previous year. This figure was below the expected $322 million forecasted by analysts.

To achieve these results, Novavax reduced its workforce by 30% since the first quarter of 2023.

Optimistic Outlook

Looking ahead to the first quarter, Novavax is anticipating revenue of approximately $100 million. Furthermore, for the full fiscal year of 2024, the company is projecting revenue to fall between $800 million and $1 billion.

Chief Executive John Jacobs expressed that 2023 marked a “transition year” for Novavax. He emphasized the company’s commitment to enhancing commercial performance in 2024 and 2025, alongside diversifying revenue opportunities with the potential launch of a combination vaccine in the fall of 2026.

These strategic moves aim to position Novavax as a more efficient and adaptable organization in the competitive landscape of vaccine manufacturing.

Direct Line Insurance Group Shares Surge

Previous article

Boston Beer Reports Significant Quarterly Losses

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News